Inventor · disambiguated record
Timothy Machajewski
Also filed as: MACHAJEWSKI TIMOTHY · MACHAJEWSKI TIMOTHY D
15 granted patents·15 pending applications·605 citations·filing 2001–2023
95Inventor score
Top patents by PatentIndex Score
30 records- 0197US6605617B2Quinolinone derivativesCHIRON CORP·Filed 2001·Granted Aug 12, 2003·174 cites·30 claims
- 0295US7064215B2Indazole benzimidazole compoundsCHIRON CORP·Filed 2002·Granted Jun 20, 2006·130 cites·27 claims
- 0395US6774237B2Quinolinone derivativesCHIRON CORP·Filed 2002·Granted Aug 10, 2004·66 cites·23 claims
- 0492US6800760B2Quinolinone derivativesCHIRON CORP·Filed 2003·Granted Oct 5, 2004·43 cites·20 claims
- 0592US6762194B2Quinolinone derivativesCHIRON CORP·Filed 2003·Granted Jul 13, 2004·46 cites·42 claims
- 0689US8865732B2Heterocyclic compounds and uses thereofHUANG ZILIN·Filed 2012·Granted Oct 21, 2014·12 cites·10 claims
- 0789US7470709B2Benzimidazole quinolinones and uses thereofNOVARTIS VACCINES & DIAGNOSTIC·Filed 2003·Granted Dec 30, 2008·36 cites·17 claims
- 0889US7335774B2Quinolinone derivativesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2005·Granted Feb 26, 2008·11 cites·12 claims
- 0986US6756383B2Heterocyclic derivatives of quinolinone benimidazolesCHIRON CORP·Filed 2001·Granted Jun 29, 2004·25 cites·14 claims
- 1084US8129394B2Heteroaryl-substituted imidazole compounds and uses thereofHUNAG ZILIN·Filed 2009·Granted Mar 6, 2012·17 cites·13 claims
- 1184US7598268B2Quinolinone derivativesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2004·Granted Oct 6, 2009·14 cites·5 claims
- 1283US7825132B2Inhibition of FGFR3 and treatment of multiple myelomaNOVARTIS VACCINES & DIAGNOSTIC·Filed 2004·Granted Nov 2, 2010·19 cites·9 claims
- 1375US7138409B2Heterocyclic compoundsCHIRON CORP·Filed 2004·Granted Nov 21, 2006·6 cites·19 claims
- 1472US7368459B2Heterocyclic compoundsCHIRON CORP·Filed 2006·Granted May 6, 2008·1 cites·14 claims
- 1567US7838527B2Methods of treating cancer and related methodsNOVARTIS VACCINES & DIAGNOSTIC·Filed 2003·Granted Nov 23, 2010·5 cites·47 claims
- 1665US2009181979A1Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical propertiesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2009·Application pending·0 cites
- 1764US2024245682A1Alpha-v-beta-8 integrin inhibitors and uses thereofPLIANT THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1863US2008070906A1Quinolinone derivativesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2007·Application pending·0 cites
- 1960US2014303182A1Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical propertiesCAI SHAOPEI·Filed 2014·Application pending·0 cites
- 2059US2013338171A1Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical PropertiesCAI SHAOPEI·Filed 2013·Application pending·0 cites
- 2159US2009281100A1Benzimidazole quinolinones and uses thereofBARSANTI PAUL A·Filed 2008·Application pending·0 cites
- 2257US2005209247A1Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical propertiesCHIRON CORP·Filed 2004·Application pending·0 cites
- 2357US2005137399A1Methods for synthesizing quinolinone compoundsCHIRON CORP·Filed 2004·Application pending·0 cites
- 2457US2003028018A1Quinolinone derivativesCHIRON COPORATION·Filed 2002·Application pending·0 cites
- 2556US2010184754A1Quinolinone derivativesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2010·Application pending·0 cites
- 2656US2012277434A1Methods for synthesizing quinolinone compoundsCAI SHAOPEI·Filed 2012·Application pending·0 cites
- 2755US2013018058A1Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical propertiesCAI SHAOPEI·Filed 2011·Application pending·0 cites
- 2854US2005203101A1Benzimidazole quinolinones and uses thereofCHIRON CORP·Filed 2004·Application pending·0 cites
- 2937US2006063219A1Trivalent metal mediated homogeneous luminescent proximity assayCHIRON CORP·Filed 2005·Application pending·0 cites
- 3037US2012225062A1Novel kinase inhibitorsBURGER MATTHEW·Filed 2012·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →